血清miR-139-5p在卵巢癌患者中的表达及其临床意义

doi:10.3760/cma.j.issn.1673422X.2018.02.008

摘要/Abstract

摘要： 目的探讨微小RNA1395p（miR1395p）在卵巢癌患者血清中的表达及其在诊断和预后判断中的临床价值。方法选取本院2009年3月至2011年12月收治的34例浆液性卵巢癌患者及同期34例女性健康体检者的血清样本。利用荧光定量PCR（RTqPCR）方法分别检测34例卵巢癌患者术前术后和34例健康对照妇女血清中miR1395p的表达情况，采用t检验进行统计学分析，并分析miR1395p在诊断和预后中的临床价值。结果miR1395p在卵巢癌患者术前血清中的表达（9.45±0.40）显著高于健康对照组（3.56±0.10），差异有统计学意义（t=14.340，P＜0.001）。卵巢癌患者术后1个月血清miR1395p表达水平（5.53±0.49）与术前相比显著降低，差异有统计学意义（t=7.800，P＜0.001）。术前血清miR1395p表达与卵巢癌患者淋巴结转移（P=0.038）相关，而与年龄（P=0.728）、临床分期（P=0.118）、肿瘤大小（P=0.732）及分化程度（P=0.071）无关。KaplanMeier生存曲线显示，miR1395p低表达的患者其中位生存时间(44.9个月)长于miR1395p高表达患者(25.9个月)，差异有统计学意义（χ2=5.721，P=0.017）。结论miR1395p在卵巢癌患者血清中表达水平显著增高，可作为卵巢癌患者诊断和预后的潜在生物标志物。

关键词: 微RNAs, 卵巢肿瘤, 血清, 诊断, 预后

Abstract: ObjectiveTo explore the expressions and clinical values of serum microRNA1395p (miR1395p) in diagnosis and prognosis of patients with ovarian cancer. MethodsFrom March 2009 to December 2011, a total of 34 patients with serous ovarian cancer and 34 female health examiners were collected in our hospital. The expressions of serum miR1395p before and after operation were detected in 34 patients with ovarian cancer and 34 healthy women by realtime quantitative polymerase chain reaction (RTqPCR). The data was analyzed by ttest. The clinical values of serum miR1395p in diagnosis and prognosis of patients with ovarian cancer were analyzed. ResultsThe expression of serum miR1395p in patients with ovarian cancer (9.45±0.40) was significantly higher than that in healthy controls (3.56±0.10), with a significant difference (t=14.340, P＜0.001). The expression of miR1395p at 1 month after operation of patients with ovarian cancer (5.53±0.49) was lower than that before operation, with a significant difference (t=7.800, P＜0.001). The expression of serum miR1395p was correlated with lymph node metastasis (P=0.038), but was not correlated with age (P=0.728), clinical stage (P=0.118), tumor size (P=0.732) and differentiation (P=0.071). KaplanMeier survival curve revealed that the median survival time of ovarian cancer patients with low serum miR1395p expression (44.9 months) was longer than that of patients with high serum miR1395p expression (25.9 months), with a significant difference (χ2=5.721, P=0.017). ConclusionThe expression of miR1395p is increased significantly in the serum of patients with ovarian cancer, which can be used as a potential biomarker for diagnosis and prognosis of patients with ovarian cancer.

Key words: MicroRNAs, Ovarian neoplasms, Serum, Diagnosis, Prognosis

张万华, 宋福婷. 血清miR-139-5p在卵巢癌患者中的表达及其临床意义[J]. 国际肿瘤学杂志, 2018, 45(2): 96-99.

ZHANG Wan-Hua, SONG Fu-Ting. Expression and clinical significance of serum miR-139-5p in patients with ovarian cancer[J]. Journal of International Oncology, 2018, 45(2): 96-99.

参考文献

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 730. DOI: 10.3322/caac.21387. ［2］ Gizzo S, Noventa M, Quaranta M, et al. A novel hysteroscopic approach for ovarian cancer screening/early diagnosis［J］. Oncol Lett, 2017, 13(2): 549553. DOI: 10.3892/ol.2016.5493. ［3］ Zheng LE, Qu JY, He F. The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer［J］. Open Med (Wars), 2016, 11(1): 125132. DOI: 10.1515/med20160024. ［4］ Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs［J］. Genome Res, 2009, 19(1): 92105. DOI: 10.1101/gr.082701.108. ［5］ Chin LJ, Slack FJ. A truth serum for cancer—microRNAs have major potential as cancer biomarkers［J］. Cell Res, 2008, 18(10): 983984. DOI: 10.1038/cr.2008.290. ［6］ Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection［J］. Proc Natl Acad Sci U S A, 2008, 105(30): 1051310518. DOI: 10.1073/pnas.0804549105. ［7］ Oliveto S, Mancino M, Manfrini N, et al. Role of microRNAs in translation regulation and cancer［J］. World J Biol Chem, 2017, 8(1): 4556. DOI: 10.4331/wjbc.v8.i1.45. ［8］ Miyoshi J, Toden S, Yoshida K, et al. MiR1395p as a novel serum biomarker for recurrence and metastasis in colorectal cancer［J］. Sci Rep, 2017, 7: 43393. DOI: 10.1038/srep43393. ［9］ Liu Z, Zhang TT, Zhao JJ, et al. The association between overweight, obesity and ovarian cancer: a metaanalysis［J］. Jpn J Clin Oncol, 2015, 45(12): 11071115. DOI: 10.1093/jjco/hyv150. ［10］ Halvorsen AR, Kristensen G, Embleton A, et al. Evaluation of prognostic and predictive significance of circulating microRNAs in ovarian cancer patients［J］. Dis Markers, 2017, 2017: 3098542. DOI: 10.1155/2017/3098542. ［11］周畅, 蒋裕芸, 严莉, 等. miR1395p在胃癌中的表达及意义［J］. 广东医学, 2015, 36(3): 371374. DOI: 10.13820/j.cnki.gdyx.2015.03.014.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[7]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[8]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[9]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[10]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[11]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[12]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[14]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.
[15]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.